Yee Chung Cheng, MD
- Zablocki VA Medical Center
- Froedtert Hospital
- Zablocki VA Medical Center
- Breast Care Center - Cancer Center - Froedtert Hospital
- Medical Oncology
- Chinese (Mandarin), Taiwanese, Chinese (Cantonese), English
To Schedule an Appointment Call
- MD - Doctor of Medicine
Yee Chung Cheng, MD, joined the Medial College of Wisconsin in 2004. He is currently an Associate Professor of Medicine in the Division of Hematology and Oncology, and the associate program director of the Hematology and Oncology Fellowship program. Dr. Cheng practices at both Froedtert Hospital/Clinical Cancer Center where he specializes and focuses his research in breast cancer, and at Clement J. Zablocki VA Medical Center where he serves as the Section Chief of Hematology and Oncology.
Dr. Cheng has completed his general Hematology and Oncology training at Baylor College of Medicine, Houston, Texas and also a specialized Blood and Marrow Transplantation training at the University of Texas M. D. Anderson Cancer Center, Houston, Texas.
His initial research interest was in the potential use of high-dose chemotherapy with hematopoietic stem cell transplantation in breast cancer. Currently his research interest is in the development of clinical trials focus on the investigative use of chemotherapy and/or novel therapy in high risk breast cancer included triple negative breast cancer or inflammatory breast cancer.
Together with his breast cancer colleagues at Froedtert Hospital/Clinical Cancer Center, Dr. Cheng has formed an inflammatory breast cancer (IBC) team to join the international IBC Connect organization led by the University of Texas M. D. Anderson Cancer Center, Houston, Texas. With the close collaboration with other renowned cancer centers in the world, we aim to provide the state of art management to inflammatory breast cancer in the state of Wisconsin.
(Chaudhary LN, Jawa Z, Hanif A, Szabo A, Kamaraju S, Cheng YC, Chitambar CR.) WMJ. 2018 Jun;117(2):62-67 PMID: 30048574 SCOPUS ID: 2-s2.0-85051516380 07/27/2018
(Dong L, Yuan Y, Opansky C, Chen Y, Aguilera-Barrantes I, Wu S, Yuan R, Cao Q, Cheng YC, Sahoo D, Silverstein RL, Ren B.) Oncotarget. 2017 Apr 04;8(14):22550-22562 PMID: 28186980 PMCID: PMC5410244 SCOPUS ID: 2-s2.0-85016933174 02/12/2017
(Cheng YC, Shi Y, Zhang MJ, Brazauskas R, Hemmer MT, Bishop MR, Nieto Y, Stadtmauer E, Ayash L, Gale RP, Lazarus H, Holmberg L, Lill M, Olsson RF, Wirk BM, Arora M, Hari P, Ueno N.) J Cancer. 2017;8(6):1009-1017 PMID: 28529613 PMCID: PMC5436253 05/23/2017
(Cheng YC, Ueno NT.) Breast Cancer. 2012 Jul;19(3):191-9 PMID: 21567170 PMCID: PMC3860359 05/14/2011
(Yao X, Hosenpud J, Chitambar CR, Charlson J, Cheng YC.) J Cancer. 2012;3:145-51 PMID: 22481980 PMCID: PMC3319980 04/07/2012
(Cheng YC, Takagi M, Milbourne A, Champlin RE, Ueno NT.) Oncologist. 2012;17(2):233-8 PMID: 22282904 PMCID: PMC3286172 01/28/2012
(Singh V, Devata S, Cheng YC.) Int J Clin Oncol. 2010 Dec;15(6):642-4 PMID: 20602134 07/06/2010
(Cheng YC, Valero V, Davis ML, Green MC, Gonzalez-Angulo AM, Theriault RL, Murray JL, Hortobagyi GN, Ueno NT.) Br J Cancer. 2010 Oct 26;103(9):1331-4 PMID: 20877352 PMCID: PMC2990606 09/30/2010
Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer.
(Cheng YC, Rondón G, Sanchez LF, McMannis JD, Couriel DR, de Lima MJ, Hosing C, Khouri IF, Giralt SA, Champlin RE, Ueno NT.) Int J Hematol. 2009 Dec;90(5):627-634 PMID: 19998065 12/10/2009
(de Souza JA, Davis ML, Rondon G, Cheng YC, Jones RB, Champlin RE, Ueno NT.) Bone Marrow Transplant. 2009 Jul;44(2):81-7 PMID: 19448681 05/19/2009
(Ahmed MS, Kroft SH, Davis NB, King DM, Cheng YC.) Leuk Res. 2008 Sep;32(9):1476-9 PMID: 18308388 SCOPUS ID: 2-s2.0-43049180001 03/01/2008
(Flejsierowicz M, Ahmed MS, Kotov P, Cheng YC.) WMJ. 2008 Jul;107(4):191-4 PMID: 18702436 08/16/2008